Moderna Q1 revenue $1.9B, net income $79M, reiterates $5B FY sales guidance

Moderna, Inc.

2023-Q1 EPS reported $0.19 revenue$1,862,000,000

Q1 revenue $1.9B (down 69% YoY); GAAP net income $79M ($0.19 EPS) vs $3.7B ($8.58 EPS) in Q1 2022.
Cost of sales 43% of product sales vs 17% prior year; includes $148M inventory write-downs and $135M idle capacity charges.
R&D spending surged 104% to $1.1B, driven by RSV, flu, CMV programs; total 2023 OpEx guided ~$6B.
RSV vaccine (mRNA-1345) met primary endpoint in older adults; expects regulatory submission and 2024 launch.
COVID-19 vaccine sales from APAs still projected at $5B for 2023; Q2 sales expected $0.2-0.3B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported the first quarter of 2023 results: revenue $1.9 billion, net income $79 million, EPS $0.19. Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: $1.9 billion
Net income: $79 million
EPS: $0.19
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.